DermaSensor

Pioneering the Future of Skin Cancer Detection

Get to know the company behind the skin cancer device that helps clinicians evaluate patients with confidence.

Current Open Roles at DermaSensor

Explore career opportunities at DermaSensor and help shape the future of AI-powered skin cancer detection.

19 hours ago

Regional Sales Manager, West Region

West region Remote Full-Time

DermaSensor is seeking a Regional Sales Manager (RSM) that is responsible for driving medical device sales, pipeline development and quarterly revenue growth within the assigned West region for its FDA-cleared optical spectroscopy solution for skin cancer risk detection. This is a highly execution-focused, customer-facing and performance-based role suited for a proven sales professional who thrives in a fast-paced, early-stage commercial environment.

View Role
19 hours ago

Customer Success Intern

Miami, FL Remote Full-Time

DermaSensor is seeking a motivated Summer Intern to support our growing Customer Success function. This temporary role is ideal for an undergraduate or graduate student interested in healthcare, medical devices, digital health, AI-enabled solutions, clinical operations, customer success, or healthcare commercialization. The intern will support customer onboarding, implementation readiness, training materials, customer follow-up and CRM system documentation. This role will provide hands-on exposure to a high-growth medical device company and the opportunity to contribute to programs that help healthcare providers successfully adopt and utilize an FDA-cleared AI-powered solution.

View Role

Our Mission

DermaSensor’s mission is to empower healthcare professionals with data-driven, breakthrough solutions that improve early skin cancer detection and save lives.

  • Integrity & Trust

    We consistently exhibit ethical conduct, transparency, and reliability in every interaction.

  • Collaborative Accountability

    We are a cohesive, adaptable team with a "can-do" attitude, taking collective ownership of the quality of our work and executional performance to achieve our business results.

  • Innovative Excellence

    We are dedicated to delivering world-class, data-driven solutions to continuously advance new standards of care.

  • People-First Dedication

    Our core purpose is to put people first - patients, providers, and their communities - through exceptional and dedicated service.

Book a Device Demo

Meet DermaSensor’s CEO, Paving the Way for Enhanced Skin Cancer Detection

As an entrepreneur and bioengineer, Cody has formed his career around delivering advanced health technologies to physicians and patients.

Request a Demo

Company Founded

As two leading entrepreneurs and investors in health technology companies, Dr. Maurice Ferre (Co-founder and Chairman) and Christopher Dewey (Co-founder and Director) came to believe that skin cancer is primarily a public health issue that could be addressed by improving access to quality skin cancer care. Due to the limited number of dermatologists, their goal was to use cutting-edge spectroscopy and machine learning technologies to improve frontline providers ability to detect skin cancer early.

They founded DermaSensor in 2009 following discussions with Dr. Irving Bigio, Professor of Biomedical Engineering at Boston University and one of the top spectroscopy researchers in the world. Dr. Bigio is the original inventor and patent holder for Elastic Scattering Spectroscopy (ESS), a key technology employed by the DermaSensor device.

Since Professor Bigio’s invention of ESS in 1994, there have been several hundreds of publications on ESS and over 30 publications on the use of ESS in clinical studies.

Start of Study for Melanoma

DermaSensor began its own skin-specific studies using this technology in 2011.

Start of Study for all Skin Cancer Types

Completion of 4th generation device, start of studies for CE Mark

DermaSensor began its first study on the current commercial device in 2018.

CE Mark under MDD after completion of CE Mark studies, FDA Pivotal study start

FDA Pivotal study and supplemental studies complete

FDA De Novo Clearance and US Launch in May

Class IIb CE Mark under MDR

Featured In Recognized media channels

80-0009.24